COVID-19 and diabetes mellitus: management of patients during the pandemic


  • N.V. Pashkovska Bukovinian State Medical University, Chernivtsi, Ukraine
  • V.I. Pankiv Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine, Kyiv, Ukraine
  • O.V. Pashkovska Charles University in Prague, Prague, the Czech Republic



diabetes mellitus, COVID-19


Coronavirus disease 2019 (COVID-19) is a potentially severe acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). People with diabetes mellitus (DM) are at increased risk of serious illness from COVID-19. DM and uncontrolled glycemia were reported as significant predictors of severity and deaths in patients infected with different viruses, including the 2009 pandemic influenza A (H1N1), SARS-CoV and MERS-CoV. In the current SARS-CoV-2 pandemic, some studies did not find a clear association between DM and disease severity. However, other reports from China and Italy showed that older patients with chronic diseases, including DM, were at higher risk for severe COVID-19 and mortality. Among COVID-19 morta­lity cases in Wuhan, China, major associated comorbidities include DM (42.3 %), hypertension (53.8 %), previous heart disease (19.2 %) and cerebral infarction (15.4 %). Also, mortality strongly increased with the presence of DM (7.3 %) and other comorbidities like cardiovascular disease (10.5 %), chronic respiratory disease, hypertension and cancer, each at 6 %. According to several studies, the prevalence of DM in people infected with the virus is about the same as in the general population, even slightly lower. A meta-analysis of 12 studies describing data from 2,108 Chinese patients with COVID-19 reported a diabetes prevalence of 10.3 %, which was similar to the national prevalence of 10.9 % reported in 2013. Patients with DM are advised to follow general guidance on risk reduction and also specific to DM. All current recommendations of healthcare organizations and scientific communities emphasise the importance of good glycemic control during the COVID-19 pandemic as it may help in reducing the risk of infection and severity.


Download data is not yet available.


Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211‐212. doi:10.1016/j.dsx.2020.03.002.

Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020;68(1):2‐5. doi:10.1007/s12020-020-02294-5.

Hartmann-Boyce J, Morris E, Goyder C, et al. Managing diabetes during the COVID-19 pandemic. The Oxford CEBM COVID-19 Evidence Service. Available from: Accessed: 2020 Apr 8.

Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract. 2020;162:108142. doi:10.1016/j.diabres.2020.108142.

Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;10.1111/all.14238. doi:10.1111/all.14238.

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720. doi:10.1056/NEJMoa2002032.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648.

Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;10.1001/jama.2020.4683. doi:10.1001/jama.2020.4683.

Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020;162:108118. doi:10.1016/j.diabres.2020.108118.

Zhou J, Tan J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism. 2020;107:154216. doi:10.1016/j.metabol.2020.154216.

Iqbal A, Prince LR, Novodvorsky P, et al. Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans. J Clin Endocrinol Metab. 2019;104(4):1187‐1199. doi:10.1210/jc.2018-01168.

Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531‐538. doi:10.1007/s00392-020-01626-9.

Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43(6):867‐869. doi:10.1007/s40618-020-01236-2.

Diabetes UK. Coronavirus and diabetes. Available from: Accessed: 2020 Apr 9.

International Diabetes Federation (IDF). Information on Corona-Virus Disease 2019 (COVID-19) outbreak and guidance for people with diabetes. Available from: Accessed: 2020 Apr 30.

Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis. Clin Ther. 2016;38(12):2654‐2664.e1. doi:10.1016/j.clinthera.2016.11.002.

Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;2010(4):CD002967. doi:10.1002/14651858.CD002967.pub4.

Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;10.1038/s41586-020-2286-9. doi:10.1038/s41586-020-2286-9.

Song Z, Xu Y, Bao L, et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019;11(1):59. doi:10.3390/v11010059.

Gentile S, Strollo F, Ceriello A. COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). Diabetes Res Clin Pract. 2020;162:108137. doi:10.1016/j.diabres.2020.108137.

Peng YD, Meng K, Guan HQ, et al. Clinical Characteristics and Outcomes of 112 Cardiovascular Disease Patients Infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E004. doi:10.3760/cma.j.cn112148-20200220-00105. (in Chinese).

World Health Organization (WHO). Coronavirus disease (COVID-19) advice for the public: Myth busters. Available from:




How to Cite

Pashkovska, N., Pankiv, V., & Pashkovska, O. (2021). COVID-19 and diabetes mellitus: management of patients during the pandemic. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), 16(3), 180–184.



Leading Article

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>